In development“It is being investigated for the treatment of chronic weight management, cardiovascular disease, heart failure, obstructive sleep apnea and Type 2 diabetes.”
Latest 10-KFY2025Impairment / charge ·
Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.
Revenue$36.8BYoY +10.0%
Net income$7.7BYoY +88.5%
Latest 10-QQ3 FY2026 ·
Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.
Revenue$10.4BYoY +8.5%
Net income$3.9BYoY +20.1%
Latest 8-KPositiveEarningsGuidance raised ·
Repatha and IMDELLTRA sales surge as biosimilars hit Prolia and XGEVA; FY2026 revenue outlook rises to $38.9B–$39.7B.
Latest 8-KLeadership change ·
Former Yum! Brands CEO David Gibbs joins the board, bringing direct customer relationship experience to inform future product launches
Latest 8-KCybersecurity incident ·
Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information
Latest 8-KShareholder vote ·
Shareholders rejected a requirement for an independent board chairman and elected all director nominees.
Latest 8-KCEO/CFO change ·
Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith, who stays through January 2027 to support the transition.
Latest 8-KDebt financing ·
Issues senior unsecured notes across four tranches, with maturities extending to 2056.
Sells it 56%, $36.5B a year“For the treatment of adults with obesity or overweight with at least one weight-related comorbid condition in combination with a reduced-calorie diet and increased physical activity; and for the treatment of moderate to severe obstructive sleep apnea in adults with obesity in combination with a reduced-calorie diet and increased physical activity (relevant indications marketed under Mounjaro in various markets outside the U.S.).”
Latest 10-KFY2025PositiveImpairment / charge ·
Mounjaro and Zepbound volume drove growth despite lower realized U.S. prices; Lilly is expanding manufacturing capacity.
Revenue$65.2BYoY +44.7%
Net income$20.6BYoY +94.9%
Latest 10-QQ3 FY2026PositiveImpairment / charge ·
Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.